Cargando...
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
During recent years, the therapeutic landscape in chronic myeloid leukemia (CML) has changed significantly. Since the clinical introduction of tyrosine kinase inhibitors (TKIs) approximately 15 years ago, patients’ concerns have shifted from reduced life expectancy toward long-term toxicities of TKI...
Gardado en:
| Publicado en: | J Blood Med |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2018
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905837/ https://ncbi.nlm.nih.gov/pubmed/29695943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S129821 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|